Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Piramal Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 149.59, up 2.13% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.57% on the day, quoting at 24216.6. The Sensex is at 78059.78, up 1.58%. Piramal Pharma Ltd has added around 7.84% in last one month.
Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has added around 0.88% in last one month and is currently quoting at 22100.1, up 1.13% on the day. The volume in the stock stood at 16.87 lakh shares today, compared to the daily average of 32.69 lakh shares in last one month.
The benchmark April futures contract for the stock is quoting at Rs 149.53, up 2.34% on the day. Piramal Pharma Ltd is down 32.57% in last one year as compared to a 3.33% gain in NIFTY and a 7.07% gain in the Nifty Pharma index.
The PE of the stock is 26.4 based on TTM earnings ending December 25.
Receipt of said EIR marks successful closure of the inspection.
In a regulatory filing made in December last year, the company said that the United States Food and Drug Administration (US FDA) conducted a general good manufacturing practices (GMP) inspection of Piramal Pharma’s Lexington (Kentucky, USA) facility from 03 December 2025 to 10 December 2025.
At the conclusion of the inspection, the US FDA issued a Form-483, with four observations.
'These observations are related to enhancement in procedures and will be classified as a VAI (voluntary action indicated). The company is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines,” Piramal Pharma had said in a statement.
Offering updates on the same, Piramal Pharma today (13 April 2026) said that the US FDA has issued an establishment inspection report (EIR) for the said manufacturing facility with VAI (voluntary action indicated).
'Receipt of said EIR marks successful closure of the inspection,' the company stated.
Piramal Pharma offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries.
The company a consolidated net loss of Rs 136.19 crore in the quarter ended December 2025 as against net profit of Rs 3.68 crore during the previous quarter ended December 2024. Sales declined 2.92% to Rs 2,139.87 crore in Q3 FY26 as compared with Q3 FY25.
The scrip rose 0.68% to currently trade at Rs 147.10 on the BSE.
Oil & gas shares tumbled after advancing in the past trading session.
At 12:25 IST, the barometer index, the S&P BSE Sensex tanked 850.50 points or 1.10% to 76,699.75. The Nifty 50 index declined 239.80 points or 0.99% to 23,811.35.
The broader market outperformed the frontline indices. The BSE 150 MidCap Index slipped 0.61% and the BSE 250 SmallCap Index fell 0.20%.
The market breadth was weak. On the BSE, 1,792 shares rose and 2,386 shares fell. A total of 197 shares were unchanged.
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, surged 9.77% to 20.69.
In the commodities market, Brent crude for June 2026 settlement rose $6.33 or 6.65% to $101.53 a barrel.
Derivatives:
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, surged 8.97% to 20.54. The Nifty 28 April 2026 futures were trading at 23,850, at a premium of 38.65 points as compared with the spot at 23,811.35.
The Nifty option chain for the 28 April 2026 expiry showed a maximum call OI of 44.2 lakh contracts at the 24,000 strike price. A maximum put OI of 50.7 lakh contracts was seen at the 23,000 strike price.
Buzzing Index:
The Nifty Oil& Gas index declined 1.56% to 11,019.05. The index rose 0.91% in the past trading session.
Hindustan Petroleum Corporation (down 3.88%), Reliance Industries (down 2.42%), Aegis Logistics (down 2.18%), Bharat Petroleum Corporation (down 2.12%), Indian Oil Corporation (down 2.09%), Petronet LNG (down 2.07%), Chennai Petroleum Corporation (down 1.88%), Gujarat State Petronet (down 1.27%), Oil & Natural Gas Corpn (down 0.59%) and Castrol India (down 0.18%) declined.
Stocks in Spotlight:
Jash Engineering rose 0.32%. The company announced that it has reported revenue of Rs 736 crore in FY26 remained largely flat compared to the consolidated audited revenue of Rs 735 crore recorded in FY25.
Oriental Rail Infrastructure declined 1.16%. The company said that it has secured an order from Rail Coach Factory (RCF), Kapurthala, under Indian Railways, for the manufacturing, supply, and installation of 25 sets of seats and berths for LHB coaches.
Piramal Pharma rose 0.17%. The company said that the USFDA has issued an establishment inspection report (EIR) for the company’s manufacturing facility located at Kentucky, USA, with VAI (voluntary action indicated). The USFDA conducted a general good manufacturing practices (GMP) inspection of Piramal Pharma’s Lexington (Kentucky, USA) facility from 03 December 2025 to 10 December 2025.At the conclusion of the inspection, the USFDA issued a Form-483, with four observations.
By combining the innovative waste anaesthesia gas capture, collection, and processing technology developed by Blue-Zone, with the global manufacturing and marketing capabilities of Piramal, this collaboration will support customers’ efforts to minimize the environmental impact of volatile anaesthetics.
This collaboration will also help ensure that these essential products remain the primary method of providing general anaesthesia for patients around the world.
Pending regulatory approval in Europe of Blue-Zone’s Phoenix Deltasorb waste anaesthetic gas capture system, Blue-Zone will offer these systems to PCC’s customers in Europe, initially in France and Germany.
Blue-Zone will be responsible for all activities involving the supply and use of its systems in healthcare facilities.
PCC will process captured waste anaesthetic gas using Blue Zone’s technology to produce Sevoflurane USP for human use in Canada.
The parties anticipate that the scope of the waste anaesthetic gas capture, collection and recycling, and the marketing of Sevoflurane USP using waste anaesthetic gas, will expand into additional geographies.
PCC is a global leader in anaesthesia, pain management and intrathecal therapy. PCC maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world.
The company a consolidated net loss of Rs 136.19 crore in the quarter ended December 2025 as against net profit of Rs 3.68 crore during the previous quarter ended December 2024. Sales declined 2.92% to Rs 2139.87 crore in Q3 FY26 as compared with Q3 FY25.
The scrip shed 0.79% to currently trade at Rs 157.15 on the BSE.
Resignation of Tanya Sanish as company secretary and compliance officer with effect from 20 February 2026.
Appointment of Pratibha Mishra (ACS No. 53432), as interim company secretary and compliance officer, KMP of the Company with effect from 21 February 2026.
Piramal Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 159.5, up 3.6% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.16% on the day, quoting at 25302.45. The Sensex is at 82334.29, down 0.01%. Piramal Pharma Ltd has dropped around 6.89% in last one month.
Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has dropped around 4.57% in last one month and is currently quoting at 21739.85, down 1.06% on the day. The volume in the stock stood at 132.69 lakh shares today, compared to the daily average of 30.98 lakh shares in last one month.
The benchmark February futures contract for the stock is quoting at Rs 157.79, up 2.3% on the day. Piramal Pharma Ltd is down 31.03% in last one year as compared to a 8.83% gain in NIFTY and a 0.42% gain in the Nifty Pharma index.
The PE of the stock is 29.05 based on TTM earnings ending September 25.